Back to News
Market Impact: 0.4
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
Source: zacks.com
Healthcare & BiotechCompany Fundamentals
argenx shares fell 12% after the company discontinued its late-stage Sjögren's disease study. Positive FB102 data in celiac disease provided a contrasting pipeline development, but the reported share decline indicates the trial discontinuation dominated the news.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
ARGX-0.65
More News
- Why is argenx stock rallying today?
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- MTY Food Group Inc Profit Retreats In Q3
- Why is T-Mobile stock tumbling today?